Rockwell Medical (NASDAQ:RMTI) Issues Earnings Results, Misses Estimates By $0.04 EPS

Rockwell Medical (NASDAQ:RMTI) released its quarterly earnings data on Thursday. The company reported ($0.02) EPS for the quarter, missing the consensus estimate of $0.02 by ($0.04), Zacks reports. Rockwell Medical had a negative net margin of 1.25% and a positive return on equity of 8.55%. The company had revenue of $24.67 million during the quarter, compared to analysts’ expectations of $23.65 million. Rockwell Medical updated its FY 2025 guidance to EPS.

Rockwell Medical Price Performance

NASDAQ RMTI opened at $1.35 on Friday. The company has a 50 day moving average price of $1.85 and a two-hundred day moving average price of $2.61. The company has a quick ratio of 2.00, a current ratio of 2.41 and a debt-to-equity ratio of 0.33. Rockwell Medical has a 12-month low of $1.26 and a 12-month high of $5.15. The stock has a market capitalization of $43.63 million, a PE ratio of -27.00 and a beta of 1.55.

Analyst Ratings Changes

A number of analysts have recently issued reports on RMTI shares. StockNews.com lowered Rockwell Medical from a “buy” rating to a “hold” rating in a research report on Friday, December 20th. HC Wainwright restated a “buy” rating and issued a $7.00 target price on shares of Rockwell Medical in a research note on Monday, December 23rd.

Rockwell Medical Company Profile

Rockwell Medical, Inc, together with its subsidiaries, operates as a healthcare company that engages in the development, manufacture, commercialization, and distribution of various hemodialysis products for dialysis providers worldwide. The company offers Triferic Dialysate and Triferic AVNU which are indicated to maintain hemoglobin in adult undergoing hemodialysis.